Cancer survivors who are younger than 65 and unable to work because of cancer-related impairments may apply for disability benefits from the Social Security Administration (SSA). To inform SSA’s disability determinations for cancer survivors, Diagnosing and Treating Adult Cancers and Associated Impairments examines advances in the prognosis, diagnosis, and treatment of cancer, Read more…
In a new study led by researchers at Yale Cancer Center (YCC), the drug enfortumab vedotin (EV) significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor. The results were Read more…
The U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect Read more…
KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the company is voluntarily withdrawing the U.S. indication for KEYTRUDA (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at Read more…
Patients with epidermal growth factor receptor (EGFR) exon 20 mutant metastatic non-small cell lung cancer (NSCLC) showed clinical benefit and tolerable safety following treatment with poziotinib according to findings presented at the ESMO Targeted Anticancer Therapies (TAT) Virtual Congress 2021 held on 1-2 March. Further study of poziotinib in patients with metastatic NSCLC Read more…
ALK – anaplastic lymphoma kinase – is an important biomarker found in NSCLC, and targeted therapies have been shown to dramatically improve progression-free survival compared to the previous standard of care(2,3,4). The VENTANA ALK (D5F3) CDx Assay(5) is now FDA approved as a companion diagnostic in four targeted treatments, providing Read more…
Cancer treatment is likely to affect every aspect of a patient’s life — their activities, relationships, eating habits, mental health, physical health and comfort, financial wellbeing. And when financial concerns weigh heavily on an individual who is in treatment for cancer, they can affect the outcome of that treatment. New research from Roswell Read more…
Annual lung cancer screening should include people as young as 50 and with shorter smoking histories, according to a new recommendation from an independent panel of experts that makes clinical recommendations to the American public. Read More…
“(March 10, 2021) approval of FOTIVDA provides a new tool for treating patients with kidney cancer who have relapsed or become refractory to two or more prior systemic therapies,” said Brian Rini, MD, Chief of Clinical Trials at Vanderbilt Ingram Cancer Center and principal investigator of the TIVO-3 trial. “With advances in RCC Read more…
If clinicians could stop mutations of the KRAS gene in pancreatic cancer – which happens in more than 90 percent of pancreatic cancer cases and drastically reduces response to immunotherapy – the chances of improving treatment for this deadly form of cancer would be increased. A collaborative study by Stony Read more…